Instem PLC

Receive alerts
Market Cap:
£59.49 m
52 weeks high
52 weeks low

Viewing results 1-25 of 58


Instem on track to meet full-year expectations as SaaS transition gains momentum

"The board expects that full-year performance will be in line with expectations."...

on 15/7/19

Instem flags share sale

A total of 1.66mln shares are being sold to “to satisfy market demand and broaden the institutional investor base”...

on 11/4/19

Instem upbeat after solid year

Chief executive Phil Reason told investors: "With increasing momentum in the business from recent contract wins and the growing pipeline, we are confident about the outlook for the Group for 2019 and beyond."...

on 1/4/19

Arecor appoints ex-IXICO CFO Susan Lowther as its new finance chief

Lowther’s first foray into the pharma and biotech sector was with US giant Monsanto, after which she has gone on to work for smaller industry players such as Novacyt, BioWisdom and, more recently, IXICO...

on 11/3/19

Demand for Instem’s SEND platform is soaring

In a January update, Instem said trading had been in-line with expectations, helped by a 500% rise in orders for its SEND platform...

on 7/3/19

Instem hails SEND platform as it delivers upbeat trading update

Instem said all three areas of the business - data collection, regulatory solutions and informatics – made “positive contributions” as it reported that profit margins had strengthened...

on 23/1/19

Huge jump in SEND orders helps Instem swing to a first-half profit; shares higher

Instem generated revenues of £10.5mln (H1 17: £10.3mln) in the opening six months of 2018, reporting a profit before tax of £0.1mln (H1 17: loss of £0.6mln)...

on 24/9/18

Instem performing well; SEND platform stars

The company has developed software used by the life sciences industry to collate and transmit data ...

on 23/7/18

Instem lands US$750,000 contract with Fortune 500 giant

The unnamed medical products and pharma company has adopted Instem's Samarind Regulatory Management System...

on 6/6/18

Instem hails contract extension for SEND platform; demand growing significantly

The client, described as a top-five pre-clinical contract research organisation, has increased the size of the deal by US$400,000 to US$500,000...

on 26/3/18

Instem's increasingly SaaSy profile should improve revenue visibility and enhance margins

Since its trading update on January 16, the stock has risen from 143p to 227p, a gain of almost 59%...

on 9/3/18

Instem sees revenue increase through client adoption of Software-as-a-Service delivery model

The AIM-listed IT solutions provider said that the decision of the client company will result in an immediate 40% rise in revenue from the client as part of a growing shift towards adoption of the SaaS offering...

on 7/3/18

Instem enjoys strong second half; bags £1.7mln contract from CRO

Revenue increases and expense reductions have delivered a strong increase in full-year profit and the sales order pipeline has once again strengthened...

on 16/1/18

Instem boss says firm is better positioned for profitable growth than ever before

"Following a period of planned strategic progress, Instem is now undoubtedly better positioned for profitable growth than ever before”...

on 26/9/17

Instem confirms revenue and profits from US NIEHS contract will be recognised in current year

The accounting treatment decided upon for the contract jibes with the line taken by investment analysts in their current year forecasts...

on 26/4/17

Instem upbeat though clinical headwinds persist

Recurring revenue and SaaS [pay-as–you-go] software revenue grew 21% and 38%...

on 28/3/17